喹硫平与氯丙嗪治疗精神分裂症临床疗效比较

Comparative analysis of the clinical efficacy of quetiapine and chlorpromazine on treatment of chizophrenia

目的 对比喹硫平与氯丙嗪治疗精神分裂症患者的临床疗效.方法 随机选取2012年3月～12月确诊为精神分裂症患者56例,根据CCMD-3精神分裂症确定标准,将首次发作的患者随机分为实验组30例与对照组26例,均接受统一的基础治疗方案,实验组30例病人给予喹硫平,首次服用100 mg/d,随后根据患者病情计量递增;对照组26例病人给予氯丙嗪,首次服用100 mg/d,随后根据病情加量.两组患者均接受6周治疗.治疗后应用简明精神病量表（BPRS）、不良反应量表（TESS）评定其疗效和不良反应.结果 实验组与对照组疗效比较,实验组痊愈5例,显效12例,有效6例,无效4例,总有效率85.2％;对照组痊愈5例,显效12例,有效8例,无效5例,总有效率83.3％,两组总有效率比较差异无显著性（P＞0.05）,而实验组的不良反应少于对照组（P＜0.05）.两组治疗后PANSS评分均低于本组治疗前（P＜0.05）,治疗前后各时间点比较,差异均无统计学意义（均P＞0.05）.实验组与对照组患者副作用发生率比较,实验组11例发生副作用,发生率36.7％,对照组17例发生副作用,发生率65.4％,实验组副作用出现率较对照组低,组间差异有统计学意义（P＜0.05）.结论 喹硫平是一种安全有效的新一代抗精神病药物,副作用少,值得在精神分裂症患者中推广使用.

Objective To investigate the efficacy of quetiapine compared with chlorpromazine in treatment of schiz- ophrenia through clinical comparison. Methods 56 patients diagnosed with schizophrenia were randomly divided into quetiapine group and chlorpromazine group. They were treated with quetiapine and chlorpromazine, respectively. Brief Psychiatric Rating Scale （BPRS） and adverse reactions scale （TESS） were observed. Results The total efficient rate of quetiapine group and chlorprornazine group were 85.2% and 83.3% （P〉0.05）. The adverse reactions of quetiapine group were less than that of chlorpromazine group. PANSS scores after treatment were lower than that before treatment. The incidence of side effects of quetiapine group and chlorpromazine group were 36.70% and 65.40% （P〈0.05）. Conclu- sion Quetiapine is a safe and effective new generation of antipsychotics.